Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab

Table 2

Comparison of functional and morphologic changes from time of switch to 24 months.

Central macular thickness (μm)	Baseline	Month 3		Month 6		Month 12	p	Month 24
ETDRS	64.4 ± 13.1	67.6 ± 12.3	0.002	67.3 ± 11	0.005	64.8 ± 13	0.6	61.4 ± 13.8	0.2
Central macular thickness (μm)	313 ± 13	312 ± 91	0.2	312 ± 14.2	0.9	313 ± 13.9	0.9	305 ± 76	0.6
Macular volume (mm^3)	7.70 ± 2.2	7.75 ± 0.16	0.8	7.8 ± 0.16	0.6	7.85 ± 0.16	0.4	7.8 ± 0.65	0.3
PED height (μm)	224.7 ± 18.5	198.5 ± 19.5	0.25	190 ± 17.3	0.5	224 ± 21	0.27	200 ± 19	0.14
Subfoveal choroidal thickness (μm)	179 ± 68					158 ± 67	0.2	174 ± 56	0.5

Data are mean ± SD unless indicated otherwise. p: continuous variables compared by independent samples t-test from baseline; BCVA: best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Scale; PED: pigment epithelial detachment.